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Sir,
Pseudomonas aeruginosa is one of the leading causes of nosocomial infections. Initiation of antimicrobial therapy is often empirical; therefore, it is important to know the susceptibility profile of pathogens in order to select the most appropriate antibiotic. This underscores the importance of using current surveillance data in order to develop rational empirical antimicrobial therapy recommendations. 1 The aim of this study was to carry out surveillance of antimicrobial susceptibility of P. aeruginosa clinical isolates in Centro Hospitalar de Coimbra (CHC) to ascertain resistance patterns in order to assist in the determination of guidelines for empirical regimens and prompt enforcement of infection control measures. CHC is a 600 bed, central hospital comprising a general, maternity and paediatric hospital, situated in the centre of Portugal, a highly populated region.
The collection period was from April 2003 to April 2006, and only one isolate per patient was included. Isolates were from inpatients with community-acquired infections (n ¼ 414) or nosocomial infections (n ¼ 685).
Identification and determination of antimicrobial susceptibilities were performed in CHC using MicroScan WalkAway (Dade Behring) and CLSI (formerly NCCLS) breakpoints. 2 Isolates with intermediate susceptibility were considered resistant in order to match better treatment decisions in clinical settings.
A multidrug-resistant (MDR) P. aeruginosa was defined as an isolate that was resistant to three or four of the following: piperacillin, ceftazidime, imipenem and ciprofloxacin.
During collection, a total of 1099 P. aeruginosa isolates were obtained in CHC, from nosocomial and community-acquired infections from different clinical specimens, including urine (17.1% and 35.5%, respectively), sputum (46.3% and 30.9%, respectively), exudates (15.6% and 13.5%, respectively), blood (4.5% and 4.6%, respectively) and other sources (16.5% and 15.5%, respectively).
Overall, susceptibility to the most commonly used antipseudomonal drugs was as follows: meropenem, 90.0%; piperacillin plus tazobactam, 89.0%; piperacillin, 86.2%; amikacin, 85.6%; ceftazidime, 85.0%; imipenem, 82.4%; aztreonam, 81.7%; ciprofloxacin, 69.2% and gentamicin, 65.9%.
Among hospital isolates, piperacillin plus tazobactam was the most potent agent (85.1% susceptible), followed by meropenem (84.8%), piperacillin (81.5%), ceftazidime (79.4%) and aztreonam (75%), and the least potent b-lactam was imipenem (74.7%). Amikacin demonstrated good activity (81.3%), but gentamicin showed poor activity (58.1%). Ciprofloxacin was only moderately active (64.2%). Community isolates were .90% susceptible to most antibiotics except for ciprofloxacin (77.3%) and gentamicin (78.7%). Meropenem was the most potent agent (98.6%) followed by piperacillin plus tazobactam (95.4%), imipenem (95.2%), ceftazidime (94.2%), piperacillin (94.0%), aztreonam and amikacin (92.8%) ( Figure 1 ).
MDR was recognized in 100 isolates (9.1%). Twenty isolates (20%) were resistant to all antibiotics tested. All these were from nosocomial infections from the principal wards and 70% were from respiratory sources. Among isolates resistant to piperacillin, ceftazidime and imipenem, ciprofloxacin demonstrated some activity (32.9%, 33.8% and 31.8%, respectively). Some ciprofloxacin-resistant isolates (27.4%) were susceptible to ceftazidime ( Table 1) .
Studies of susceptibility held in Europe by MYSTIC and SENTRY demonstrated superior activity of meropenem and piperacillin plus tazobactam. 3, 4 In our work, among nosocomial isolates, piperacillin plus tazobactam showed the best activity followed by meropenem. In CHC, imipenem was the worst among the b-lactams, with decreased activity over the 3 years of this study (10.9% decrease in susceptibility).
A study by European Surveillance of Antimicrobial Consumption demonstrated that Portugal (with Spain and Italy) was the European country with the highest fluoroquinolone use. 5 Misuse of fluoroquinolones may, therefore, explain the low susceptibility of our isolates, whether they were from community (77.2% susceptible) or from hospital (64.2%). MYSTIC and SENTRY studies also revealed low susceptibility to these agents. 3, 4 Incidence of MDR isolates was high, but within the results observed in Europe. 6 Choices of antimicrobial agents for empirical therapy for possible pseudomonal infections must be influenced by regional information as well as by changing local patterns of resistance. 4 Since none of the antibiotics tested among nosocomial isolates reached 90% susceptibility, recommendations for empirical treatment are difficult to give, although piperacillin plus tazobactam and meropenem seem a good choice for initial therapy. Monotherapy carries the risk of possible emergence of antibiotic-resistant bacteria during treatment, and combination therapy, including a b-lactam (carbapenem or piperacillin plus tazobactam) and an aminoglycoside (amikacin), may be a prudent option, especially in cases of severe infection. 1 Among community isolates, all b-lactams would be useful as, in this study, P. aeruginosa was in general susceptible to these agents.
In conclusion, surveillance of antimicrobial susceptibility is important for developing rational empirical therapy guidelines and for guiding efforts to control and prevent spread of resistant microorganisms, especially if, like P. aeruginosa, they show particular propensity for the development of resistance and are a recognized public health threat. Sir, Imipenem-resistant Acinetobacter baumannii (IRAB) infections and nosocomial outbreaks have been reported in many countries. Epidemic strains of IRAB are often resistant to many other antimicrobial agents, including aminoglycosides. One of the most important mechanisms of aminoglycoside resistance is posttranscriptional rRNA methylation by 16S rRNA methylases. The first 16S rRNA methylase gene, rmtA, was reported in a strain of Pseudomonas aeruginosa in Japan in 2002. 1 Other methylase genes (rmtB, rmtC, rmtD and armA) were discovered sequentially, and emerged in isolates from both patients and animals. 1 -6 Three hundred and forty-two non-duplicate IRABs, screened by agar dilution method according to the CLSI 2006 guidelines, 7 were recovered from 19 hospitals of six provinces in China from December 2004 to December 2005. Among these IRABs, 271 isolates were collected from 14 hospitals in 11 cities representative of the 11 districts of Zhejiang province and 71 isolates from five hospitals of five other provinces ( Table 1 ). All isolates were assigned to the Acinetobacter calcoaceticus -A. baumannii complex by Vitek GNI þ card (bioMérieux, France). Species were identified by sequence analysis of the 16S -23S rRNA gene spacer region. 8 The MICs of five aminoglycoside agents against 342 IRABs were determined by agar dilution method as defined by the CLSI. 7 Escherichia coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as reference strains. The aminoglycoside agents tested in this study were amikacin (Sigma, Germany), gentamicin (Sigma, Germany), tobramycin (Sigma, Germany), 
